Abstract: The invention provides compounds of the general formula: ##STR1## The compounds have hemoregulatory activities and can be used to stimulate haematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
July 7, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Pradip Kumar Bhatnagar, William Francis Huffman, James Edward Talmadge
Abstract: The present invention relates to novel dimers of 4.4-(disubstituted)cyclohexan-1-ol dimers and delated compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
Type:
Grant
Filed:
June 23, 1997
Date of Patent:
July 7, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Siegfried B. Christensen, IV, Joseph M. Karpinski
Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
July 7, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler
Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): ##STR1## in which: R.sup.1 is hydrogen or an organic substituent group;R.sup.2 is a fused bicyclic heterocyclic ring system of general formula: ##STR2## wherein R.sup.4 and R.sup.5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R.sup.3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol .dbd./.dbd. indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
July 7, 1998
Assignee:
Smithkline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor
Abstract: The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction.
Abstract: The invention provides Response regulator polypeptides and DNA (RNA) encoding Response regulator polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Response regulator polypeptides to screen for antibacterial compounds.
Abstract: This invention describes the use of aminoindane and amino-tetrahydronaphthalene derivatives of general formula (I) ##STR1## in which Ar, X, R.sub.1, R.sub.2 and n are defined in claim 1, for the manufacture of a medicament for the treatment of disorders in which a calcium channel antagonist is indicated. Novel compounds falling within formula (I) are also claimed.
Abstract: This invention relates to libraries of non-peptide compounds each comprised of a core structure and methods for making such libraries. This invention also relates to novel silicon-based polymer resins and silane linkers, methods for their preparation and their use in the synthesis of libraries of compounds to be screened as pharmaceutical agents.
Type:
Grant
Filed:
June 12, 1996
Date of Patent:
June 30, 1998
Assignee:
SmithKline Beecham Corp.
Inventors:
Balan Chenera, John Elliott, Michael Moore, Joseph Weinstock
Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1 represents ##STR2## in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; andR.sub.3 is CN;said process comprising reacting a compound of formula (II): ##STR3## wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.
Type:
Grant
Filed:
May 12, 1995
Date of Patent:
June 30, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Steven Mark Bromidge, Martyn Voyle, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Gary Thomas Borrett
Abstract: The present invention relates to novel 3,3-(disubstituted)-cyclohexan-1-ylidene acetate dimers of Formula (I): ##STR1## and related compounds, pharmaceutical compositions containing these compounds, and their use in treating allergic and inflammateory diseases and for inhibiting the production of Tumor Necrosis Factor (TNF).
Type:
Grant
Filed:
June 23, 1997
Date of Patent:
June 16, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Siegfried B. Christensen, IV, Joseph M. Karpinski
Abstract: The invention provides Response Regulator polypeptides and DNA (RNA) encoding Response Regulator polyepoxides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Response Regulator polypeptides to screen for antibacterial compounds.
Abstract: Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein coupled receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein coupled receptor nucleic acid sequences and an altered level of the soluble form of the receptors.
Type:
Grant
Filed:
August 14, 1996
Date of Patent:
June 9, 1998
Assignees:
Human Genome Science, Inc., Takeda
Inventors:
Ryo Fujii, Shuji Hinuma, Yi Li, Steven M. Ruben, Daniel R. Soppet
Abstract: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
June 9, 1998
Assignee:
SmithKline Beecham p.l.c.
Inventors:
John Edward Hodgson, Elizabeth Jane Lawlor
Abstract: The present invention relates to novel peptides which have hemoregulatory activities and can be used to inhibit the myelopoietic system of humans and animals.
Type:
Grant
Filed:
May 25, 1994
Date of Patent:
June 2, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Pradip Kumar Bhatnagar, William Francis Huffman
Abstract: The invention provides FabH polypeptides and DNA (RNA) encoding such FabH and a procedure for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such FabH for the treatment of infection, particularly bacterial infections. Antagonists against such FabH and their use as a therapeutic to treat infections, particularly bacterial infections are also provided. Further provided are diagnostic assays for detecting diseases related to the presence of FabH nucleic acid sequences and the polypeptides in a host. Also provided are diagnostic assays for detecting polynucleotides encoding novel Fab family proteins and for detecting such polypeptides in a host.
Type:
Grant
Filed:
November 18, 1996
Date of Patent:
June 2, 1998
Assignee:
SmithKline Beecham Corporation
Inventors:
Daniel Robert Gentry, John Timothy Lonsdale, David John Payne, Stewart Campbell Pearson
Abstract: A method of treatment using a compound of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R.sub.2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R.sub.3 is hydrogen or lower alkyl of up to 6 carbon atoms;R.sub.4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R.sub.4 together with R.sub.5 can represent --CH.sub.2 --O--;X is a valency bond, --CH.sub.2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;R.sub.5 and R.sub.6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH.sub.2 -- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; orR.sub.5 and R.sub.